BioTuesdays

Tag - Brookline

Hepion Pharmaceuticals
Markets

Brookline starts Hepion Pharma at buy; PT $12

Brookline Capital Markets launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $12 price target. The stock closed at $3.39 on Nov. 21. Hepion is developing CRV431, a novel pleiotropic...

November 22, 2019
Scynexis Logo
Markets

Brookline starts SCYNEXIS at buy; PT $5

Brookline Capital Markets launched coverage of SCYNEXIS (NASDAQ:SCYX) with a “buy” rating and $5 price target. The stock closed at $1.07 on Aug. 19. Analyst Kumaraguru Raja writes that SCYNEXIS’ lead product candidate...

August 20, 2019
Markets

Brookline starts Vaxart at buy; PT $6

Brookline Capital Markets launched coverage of Vaxart (NASDAQ:VXRT) with a “buy’ rating and $6 price target. The stock closed at 66 cents on Aug. 14. Vaxart is focused on oral, recombinant vaccines that are expected to...

August 15, 2019
Cellectar Biosciences
Markets

Brookline starts Cellectar Biosciences at buy; PT $6

Brookline Capital Markets launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and price target of $6. The stock closed at $2.14 on July 29. Cellectar has a unique cancer target delivery platform...

July 30, 2019
Markets

Brookline starts Progenics Pharma at buy; PT $10

Brookline Capital Markets initiated coverage of Progenics Pharmaceuticals (NASDAQ:PGNX) with a “buy” rating and $10 price target. The stock closed at $5.25 on July 29. “We expect that Progenics is well poised to ramp up...

July 30, 2019
Heat Biologics
Markets

Brookline starts Heat Biologics at buy; PT $8

Brookline Capital Markets launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $8 price target. The stock closed at 52 cents on July 29. Heat Biologics has cell-therapy platforms called ImPACT and...

July 30, 2019
Markets

Brookline starts Veru at buy; PT $12

Brookline Capital Markets initiated coverage of Veru (NASDAQ:VERU) with a “buy” rating and $12 price target. The stock closed at $2.23 on July 29. “In our view, VERU-111 and zuclomiphene have potential to be value...

July 30, 2019
Celsion
Markets

Brookline starts Celsion at buy; PT $9

Brookline Capital Markets launched coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $9 price target. The stock closed at $1.79 on July 25. Celsion is focused on clinical-stage oncology products and platform...

July 26, 2019
Markets

Brookline starts Chiasma at buy; PT $15

Brookline Capital Markets initiated coverage of Chiasma (NASDAQ:CHMA) with a “buy” rating and $15 price target. Chiasma is developing Mycapssa as potential maintenance treatment for adults with acromegaly, a hormonal...

July 25, 2019